Asgard Therapeutics was shortlisted as a finalist of the 2021 Merck EU Advance Biotech Grants Program. This program aims to support emerging biotech companies pushing innovative drugs to the market by allowing grant recipients to receive free products and services.
Asgard Therapeutics awarded with Sweden’s SWElife Innovation Grant
Asgard Therapeutics was awarded with Sweden’s SWElife innovation grant to support the project “Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC” in collaboration with Dr. Lennart Greiff from the Department of Otorhinolaryngology, Head & Neck Surgery, Skåne University Hospital (Lund) and Professor Malin Lindstedt from the Department of Immunotechnology at Lund University. The purpose of this project is to perform preclinical validation and clinical trial design of TrojanDC for Head & Neck cancer treatment.
Swelife is a strategic innovation programe, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programe’s partners. Swelife supports collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
Fábio Rosa highlighted as one of the young 34 promising Scanian personalities of 2020
Rapidus and PwC highlighted Fábio Rosa as one of 34 young promising Scanian personalities and driven entrepreneurs of this year.
Asgard Therapeutics highlighted at the Medicon Valley Alliance/ Øresundsinstituttet report
In a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne.
Filipe Pereira awarded with Mats Paulsson Grant 2020
Mats Paulsson Foundations awarded Filipe Pereira, co-founder of Asgard Therapeutics, with a Mats Paulsson Grant 2020. Since 2019, the foundation has focused on grants for academic research projects that in the near future can lead to socially beneficial innovations.
Filipe Pereira awarded with the KiiLN Postdoctoral Entrepreneurship Award
The KiiLN- Keystone for Incubating Innovation in Life Sciences Network team and Icahn School of Medicine at Mount Sinai awarded Filipe Pereira, co-founder of Asgard Therapeutics, the KiiLN Postdoctoral Entrepreneurship Award. This award recognizes Filipe’s efforts in entrepreneurship addressing unmet needs in life sciences.
Asgard Therapeutics becomes a SmiLe member
Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC.
https://news.smileincubator.com/posts/pressreleases/immunotherapy-company-asgard-therapeutics-is
Asgard featured on the Pharma Industry report about ATMPs in Sweden
Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader in ATMPs and for this it is important to manage research efforts in an efficient way, facilitating the clinical translation of such innovative therapies. Within this thematic, Pharma Industry Publishing AB published a report on the development of ATMPs in Sweden, where Asgard Therapeutics was featured.
Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations
Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations. The award is intended to promote and encourage the utilization of knowledge at Lund University.
https://www.lu.se/index.php/artikel/framtidens-innovationer-prisade-i-lund
Filipe Pereira, co-founder of Asgard Therapeutics, awarded with a BII PreSeed grant
The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.